<< Scientists discover how omega-3 fatty acids shut down inflammation and reverse diabetes | Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Ελληνικά | Русский | Svenska | Polski

Research on immune system can develop new therapy for inflammation, tumors

Published on September 3, 2010 at 5:55 AM · No Comments

New findings may lead to the development of more effective therapies for inflammation, wounds and malignant tumors

In two closely related studies, two teams of Scripps Research Institute scientists have discovered the underlying mechanisms that activate a type of immune cell in the skin and other organs. The findings may lead to the development of new therapies to treat inflammation, wounds, asthma, and malignant tumors.

The results of the two companion studies were published in the September 3, 2010 issue of the prestigious journal Science. Together, the new research sheds light on γδ (pronounced "gamma delta") T cells, an immune cell found within epithelial tissues-the thin layer of cells that makes up the outermost layer of skin and organs like the intestines and lungs.

"These cells play unique and critical roles in recognition of damage or disease in epithelial tissues," said Scripps Research Professor Wendy Havran, who headed up one of the projects. "Our study identified a new costimulatory molecule for γδ T cells that directs the wound healing abilities of these cells."

The other team, led by Scripps Research Professor Ian Wilson, focused on the underlying mechanisms of γδ T cell costimulation, which until now have remained elusive.

"Our focus was to uncover the molecular details in the cell-signaling process of γδ T cells," said Wilson. "Using x-ray crystallography, we were able to get a three-dimensional view of a costimulatory receptor-ligand pair for γδ T cells. Our two studies, together, move the basic science and understanding of γδ T cells to a new level."

Coaxing Secrets from γδ T cells Before several recent studies of γδ T cells by scientists at Scripps Research and elsewhere, little had been learned about the activation mechanisms of γδ T cells in the nearly three decades since their discovery. Scientists found that these cells arise early in fetal development in the thymus, and from there migrate to epithelial tissues.

Unlike the αβ ("alpha beta") T cells of the immune system (that are launched on a search-and-destroy mission when the skin suffers a cut or other damage), most γδ T cells do not circulate through the bloodstream. Instead, they are a major T cell component of the skin, lung, and intestine, where they take up residence and monitor the neighboring epithelial cells for damage and disease.

But do γδ T cells play other, perhaps more important biological roles in the body? This question was the focus of a Havran-led study eight years ago, which found that when skin is cut or damaged wound healing occurs faster with help from γδ T cells.

Following this study, Havran headed up two successful projects to discover exactly how the γδ T cells speed wound healing. Her team postulated-and showed-that the keratinocytes, the major type of epithelial cell in the epidermis, sense damage to the skin and then express an antigen (i.e. a molecule recognized by the immune system). This antigen is recognized by the γδ T cells, which then become activated and undergo a morphological change to become little round factories. These begin mass-producing a growth factor that binds to keratinocytes and other epithelial cells, helping them proliferate and leading to the closure of the wound. The γδ T cells also multiply to increase the wound-healing response.

Getting Down to the Basics of γδ T Cells

In the new studies, the Havran and Wilson labs combined their expertise to answer the question: Which molecules are important for the activation of γδ T cells?

Wilson came to the current study after more than 20 years of work on the structure and function of αβ T cells. In 1996, his research team was the first to solve the structure of the αβ T cell receptor.

"To become activated in your body, T cells need recognition of an antigen by the T cell receptor," Wilson explained. "And from studies on αβ T cells, we know that for most T cells, one signal is not sufficient; they need a second, or costimulatory signal. For αβ T cells, that process has been well described. What we didn't know going into this current study whether γδ T cells required a second signal or not."

These two papers do in fact identify a junctional adhesion molecule, JAML, as a new costimulatory receptor for γδ T cells that binds to the ligand CAR (coxsackie and adenovirus receptor) expressed on keratinocytes.

"When there's damage or disease, the molecules we've identified are up-regulated," said Wilson, "and signals that are transmitted through their interaction with each other costimulate a T cell response that aids in tissue repair or killing of tumors."

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading